November 30, 2016 - By kentuckypostne · 0 Comments
The stock of Loncar Cancer Immunotherapy Etf (NASDAQ:CNCR) registered a decrease of 40% in short interest. CNCR’s total short interest was 3,000 shares in November as published by FINRA. Its down 40% from 5,000 shares, reported previously. With 7,700 shares average volume, it will take short sellers 0 days to cover their CNCR’s short positions. The ETF decreased 1.72% or $0.41 on November 29, hitting $23.39. Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) has risen 0.43% since April 27, 2016 and is uptrending. It has underperformed by 4.80% the S&P500.
More notable recent Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) news were published by: Businesswire.com which released: “Market’s Only Cancer Immunotherapy ETF Launches” on October 14, 2015, also Seekingalpha.com with their article: “Cancer Immunotherapy ETF Takes Curious Approach To Asset Allocation” published on November 19, 2015, Seekingalpha.com published: “The First Cancer Immunotherapy ETF” on October 16, 2015. More interesting news about Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) were released by: Thestreet.com and their article: “Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched” published on April 07, 2015 as well as Thestreet.com‘s news article titled: “Cancer Immunotherapy ETF Offers High Growth Investing Potential” with publication date: December 14, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.